Aastrom Biosciences Reports Third-Quarter 2014 Financial Results
November 13, 2014 08:16 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 2014
November 05, 2014 16:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
October 09, 2014 17:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 17, 2014 08:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI(TM) at the 2015 American Academy of Orthopedic Surgeons Annual Meeting
September 16, 2014 08:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Announces Pricing of Public Offering of Common Stock
September 11, 2014 08:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy
August 22, 2014 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 22, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Biosciences Reports Second Quarter 2014 Financial Results
August 14, 2014 07:30 ET
|
Aastrom Biosciences, Inc.
U.S. Commercial Business Generates Positive Contribution
Conference Call Today at 8:30 a.m. Eastern Time
ANN ARBOR, Mich., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc....
Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 2014
August 11, 2014 09:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Aastrom Announces Appointment of Zac Taylor as National Sales Director
July 14, 2014 08:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., July 14, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...